Next Article in Journal
Postoperative Radiotherapy Option Based on Mediastinal Lymph Node Reclassification for Patients with pN2 Non-small-Cell Lung Cancer
Previous Article in Journal
Access to Cancer Care in Northwestern Ontario—A Population-Based Study Using Administrative Data
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 3
10.3747/co.27.5869
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study

by
A. Deruchie Tan
1,
K. Willemsma
1,
A. MacNeill
2,
K. DeVries
3,
A. Srikanthan
1,
C. McGahan
3,
T. Hamilton
2,
H. Li
1,
C.D. Blanke
4 and
C.E. Simmons
1,*
1
Medical Oncology, BC Cancer, Vancouver, BC, Canada
2
Surgical Oncology, BC Cancer, Vancouver, BC, Canada
3
Statistical Sciences, BC Cancer, Vancouver, BC, Canada
4
Medical Oncology, ohsu Knight Cancer Institute, Portland, OR, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(3), 276-282; https://doi.org/10.3747/co.27.5869
Submission received: 3 March 2020 / Revised: 5 April 2020 / Accepted: 7 May 2020 / Published: 1 June 2020

Abstract

Background: The real-world impact of tyrosine kinase inhibitors (tkis) in clinical practice for gastrointestinal stromal tumour (gist) has not been extensively reported. We sought to assess how outcomes have changed over the eras and to evaluate the effect of access to imatinib and sunitinib on survival in patients with unresectable or metastatic gist in British Columbia. Methods: Patients with metastatic or unresectable gist were allocated to one of three eras: pre-2002, 2002–2007, and post-2007 based on treatment availability (pre-imatinib, post-imatinib, and post-sunitinib). Overall survival (os) and progression-free survival (pfs) were compared between eras. Univariate and multivariate analyses were performed to determine the effects of tumour, patient, and treatment characteristics on survival outcomes. Results: Of 657 patients diagnosed with gist throughout British Columbia during 1996–2016, 196 had metastatic disease: 23 in the pre-imatinib era, 67 in the post-imatinib era, and 106 in the post-sunitinib era. A significant increase in os, by 53.6 months (p = 0.0007), and pfs, by 29.1 months (p = 0.044), was observed after the introduction of imatinib. The introduction of sunitinib did not significantly affect os or pfs. Conclusions: Implementation of tkis has drastically improved survival outcomes for patients with metastatic gist by up to 4.55 years in the real-world setting. Our study demonstrates that implementation of tkis in clinical practice has outperformed their benefit predicted in clinical trials.
Keywords: gist; gastrointestinal stromal tumour; tyrosine kinase inhibitors; imatinib; sunitinib; sarcoma; real-world data gist; gastrointestinal stromal tumour; tyrosine kinase inhibitors; imatinib; sunitinib; sarcoma; real-world data

Share and Cite

MDPI and ACS Style

Tan, A.D.; Willemsma, K.; MacNeill, A.; DeVries, K.; Srikanthan, A.; McGahan, C.; Hamilton, T.; Li, H.; Blanke, C.D.; Simmons, C.E. Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study. Curr. Oncol. 2020, 27, 276-282. https://doi.org/10.3747/co.27.5869

AMA Style

Tan AD, Willemsma K, MacNeill A, DeVries K, Srikanthan A, McGahan C, Hamilton T, Li H, Blanke CD, Simmons CE. Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study. Current Oncology. 2020; 27(3):276-282. https://doi.org/10.3747/co.27.5869

Chicago/Turabian Style

Tan, A. Deruchie, K. Willemsma, A. MacNeill, K. DeVries, A. Srikanthan, C. McGahan, T. Hamilton, H. Li, C.D. Blanke, and C.E. Simmons. 2020. "Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study" Current Oncology 27, no. 3: 276-282. https://doi.org/10.3747/co.27.5869

APA Style

Tan, A. D., Willemsma, K., MacNeill, A., DeVries, K., Srikanthan, A., McGahan, C., Hamilton, T., Li, H., Blanke, C. D., & Simmons, C. E. (2020). Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study. Current Oncology, 27(3), 276-282. https://doi.org/10.3747/co.27.5869

Article Metrics

Back to TopTop